在帕金森病中预防病:指导方针和差距
Richard Camicioli1, Meg E Morris2, Frederico Pieruccini-Faria3,4
1Department of Medicine (Neurology) and Neuroscience and Mental Health Institute University of Alberta Edmonton Alberta Canada.
Movement disorders clinical practice
|October 23, 2023
概括
患有帕金森病的人经常跌倒. 有针对性的运动,药物治疗以及解决个人和系统障碍对于有效预防PD的跌倒至关重要.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 物理疗法物理治疗
背景情况:
- 患有帕金森病 (PD) 的个人表现出明显增加的跌倒风险.
- 布对PD患者的健康和独立性构成重大威胁.
研究的目的:
- 针对帕金森病患者,确定当前防摔策略的缺口,特别是针对帕金森病患者.
- 为全球老年人预防跌倒指南的制定提供信息,重点关注PD.
主要方法:
- 一个德尔菲的共识过程被用来建立PD下降的具体建议.
- 进行了叙事审查,以提供教育背景,并确定预防差距.
主要成果:
- 虽然建议运动,但最佳类型,活动和PD子组受益需要进一步研究.
- 在PD中,主要的跌倒风险因素包括步行结,步行速度降低和跌倒史.
- 多模式干预,高级PD的监督培训,以及胆酶抑制剂等药物显示出有前途. 在个人,环境,政策和卫生系统层面存在障碍.
结论:
- 具体的,有针对性的策略对于减轻帕金森病中跌倒风险至关重要.
- 需要对各种PD子组的运动方式和定制干预措施进行进一步的研究.
相关概念视频
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K


